Foghorn Therapeutics Inc. 8-K Report: Key Insights on December 29, 2024 Filing

Based on the provided section of the financial report, here are the key points and insights extracted:

1. Company Identification:

• Name: Foghorn Therapeutics Inc.
• CIK Number: 0001822462
• State of Incorporation: Delaware (DE)
• IRS Employer Identification Number (EIN): 47-5271393

2. Report Type:

• The filing is an 8-K, which is used to report major events that shareholders should know about.

3. Reporting Period:

• Date of Filing: December 29, 2024
• Reporting Period: The report covers the specific date of December 29, 2024.

4. Contact Information:

• Address: 500 Technology Square, Ste 700, Cambridge, MA 02139
• Phone Number: 617-586-3100

5. Securities Information:

• Type of Security: Common Stock
• Par Value: $0.0001 per share
• Ticker Symbol: FHTX
• Exchange: NASDAQ

Insights:

• The 8-K filing indicates that Foghorn Therapeutics is likely reporting a significant event on December 29, 2024, which could impact its operations or financial status.
• The specific par value of the common stock suggests that the company is structured to allow for a very low capital base, which may be strategic for fundraising or issuing new stock.
• Being listed on NASDAQ indicates that the company is subject to stringent reporting requirements and regulatory oversight, which could reflect on its corporate governance and operational transparency.
• The contact information provides a direct line for investors or stakeholders to inquire further about the company’s operations or the specifics of the filing.

This information is crucial for investors, analysts, and stakeholders to assess the company's current standing and potential future events that may influence its market performance.